Nader Rahimi, PhD

Associate Professor, Pathology & Laboratory Medicine

Nader Rahimi
617.638.5011
670 Albany St Biosquare III

Biography

I have a broad expertise in cell signaling in particular in receptor tyrosine kinases, protein modification (phosphorylation, methylation, ubiquitination, acetylation and proteolytic cleavage modifications). We are also expert in various mouse and cell culture based angiogenesis and tumor models.

Other Positions

  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Division of Graduate Medical Sciences
  • Associate Professor, Ophthalmology, Boston University School of Medicine

Education

  • Queen's University, PhD
  • Queen's University, MS
  • University of Toronto, BS

Publications

  • Published on 7/17/2018

    Kumaradevan S, Lee SY, Richards S, Lyle C, Zhao Q, Tapan U, Jiangliu Y, Ghumman S, Walker J, Belghasem M, Arinze N, Kuhnen A, Weinberg J, Francis J, Hartshorn K, Kolachalama VB, Cifuentes D, Rahimi N, Chitalia VC. c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/ß-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation. Am J Pathol. 2018 Aug; 188(8):1921-1933. PMID: 30029779.

    Read at: PubMed
  • Published on 6/1/2018

    Ho RX, Meyer RD, Chandler KB, Ersoy E, Park M, Bondzie PA, Rahimi N, Xu H, Costello CE, Rahimi N. MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast cancer growth. J Mol Cell Biol. 2018 Jun 01; 10(3):195-204. PMID: 29329397.

    Read at: PubMed
  • Published on 12/26/2017

    Meyer RD, Zou X, Ali M, Ersoy E, Bondzie PA, Lavaei M, Alexandrov I, Henderson J, Rahimi N. TMIGD1 acts as a tumor suppressor through regulation of p21Cip1/p27Kip1 in renal cancer. Oncotarget. 2018 Feb 09; 9(11):9672-9684. PMID: 29515762.

    Read at: PubMed
  • Published on 12/18/2017

    Rahimi N. Defenders and Challengers of Endothelial Barrier Function. Front Immunol. 2017; 8:1847. PMID: 29326721.

    Read at: PubMed
  • Published on 9/18/2017

    Woolf N, Pearson BE, Bondzie PA, Meyer RD, Lavaei M, Belkina AC, Chitalia V, Rahimi N. Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy. Oncogenesis. 2017 Sep 18; 6(9):e378. PMID: 28920928.

    Read at: PubMed
  • Published on 12/29/2016

    Chandler KB, Leon DR, Meyer RD, Rahimi N, Costello CE. Site-Specific N-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2. J Proteome Res. 2017 Feb 03; 16(2):677-688. PMID: 27966990.

    Read at: PubMed
  • Published on 11/9/2016

    Wang YH, Meyer RD, Bondzie PA, Jiang Y, Rahimi I, Rezazadeh K, Mehta M, Laver NM, Costello CE, Rahimi N. IGPR-1 Is Required for Endothelial Cell-Cell Adhesion and Barrier Function. J Mol Biol. 2016 Dec 04; 428(24 Pt B):5019-5033. PMID: 27838321.

    Read at: PubMed
  • Published on 11/1/2016

    Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150. PMID: 27661103.

    Read at: PubMed
  • Published on 3/24/2016

    Nader Rahimi 24.03.2016. THERAPEUTIC AND RESEARCH APPLICATION OF PDCL3. 2016.

    Read at: Custom
  • Published on 12/21/2015

    Maghsoudlou A, Meyer RD, Rezazadeh K, Arafa E, Pudney J, Hartsough E, Rahimi N. RNF121 Inhibits Angiogenic Growth Factor Signaling by Restricting Cell Surface Expression of VEGFR-2. Traffic. 2016 Mar; 17(3):289-300. PMID: 26602861.

    Read at: PubMed

View 46 more publications: View full profile at BUMC

View all profiles